Somantadine, an adamantane derivative, is an antiviral agent. Somantadine was synthesized by Pennwalt and has been undergoing tests for the treatment of herpes virus for nearly five years.

FEPRADINOL is an analgesic, antipyretic and anti-inflammatory agent. Its anti-inflammatory activity does not seem to be related to an inhibitory effect on prostaglandin biosynthesis.

Brecanavir (previously known as VX-385), a HIV aspartyl protease inhibitor was developed for the treatment of HIV. The inhibition of HIV viral proteinase enzyme prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Brecanavir reached Phase II development. However, GlaxoSmithKline announced to discontinue development brecanavir. Because of the inability to develop a viable oral dosage formulation capable of delivering the desired brecanavir levels in patients with multi-drug resistant HIV.

Parconazole is used in veterinary as an oral fungicide with a broad-spectrum activity against dermatophytes, yeasts, and others fungi. This compound does not have any antibacterial effect. The mechanism of action involves inhibition of the fungal cytochrome P450 dependent 14alpha-dimethylation of lanosterol to ergosterol.

Memotine (UK2371)is an isoquinoline antiviral compound. In vitro, it is active against myxoviruses and paramyxoviruses. It is not active against rhinoviruses. Memotine given orally reduces the antibody response and the incidence of clinical reactions.

Cefuracetime is an impurity of Cefuroxime, which is an antibacterial agent.

Toliodium is a surfactant used as an antibacterial and antiseptic agent. Also, it was used as an animal food additive.

Diathymosulfone is an antibacterial agent. It was used as antimycobacterial and leprostatic drug.

Propikacin (also known as UK31214) is kanamycin B derivative patented by Pfizer Inc. as antibacterial compound. In preclinical studies Propikacin shows antibacterial activity against the Enterobacteriaceae, P. stuartii strains and the gentamicin-resistant strains of P. aeruginosa.

Cuprimyxin is a topical antibiotic with considerable antibacterial, anti-yeast, and antifungal activity in veterinary applications without the irritation side effects. Cuprimyxin was formulated in cream and tested in vitro against Gram-positive and Gram-negative bacterial and fungal pathogens and yeast infections, in vivo as a cream for otic and ophthalmic infections, and as a suspension with hydrocortisone acetate for the treatment of otitis. The apparent biological mechanism of action involves alteration of the invading bacterial DNA template